Coloplast AS EBIT

The latest EBIT for CLPBY is $5.9B as of March 2026. That compares with $7.4B in the prior-year period — down 20.8% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Coloplast AS's historical trend and sector peers before judging valuation or financial health.

Over the past year, CLPBY's EBIT moved from $7.4B to $5.9B — a 20.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Coloplast AS's operating scale or balance-sheet position.

Against Healthcare companies, CLPBY currently prints $5.9B for EBIT, while the sector average sits near $23B. That is roughly 74.7% below the sector mean. Large gaps often invite a closer look at Coloplast AS's growth, margins, and balance sheet.

A EBIT figure of $5.9B for CLPBY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting CLPBY's EBIT ($5.9B), review year-over-year change from $7.4B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.